

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Filling the gap in antiphospholipid syndrome diagnosis: a patient's story

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1727948> since 2020-03-19T15:16:21Z

Published version:

DOI:10.1177/0961203320903810

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Lupus. 2020 Jan 29:961203320903810. doi: 10.1177/0961203320903810. [Epub ahead of print]

Filling the gap in antiphospholipid syndrome diagnosis: a patient's story.

Sciascia S, Radin M, Baldovino S, Roccatello D.

The publisher's version is available at:

https://journals.sagepub.com/doi/abs/10.1177/0961203320903810?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=lupa

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/2318/1727948>

This full text was downloaded from iris-AperTO: <https://iris.unito.it/>

Filling the gap in antiphospholipid syndrome diagnosis: a patient's story

Sciascia, Savino¹; Radin, Massimo^{1,2}; Baldovino, Simone^{1,2}; Roccatello, Dario¹.

¹CenterforResearch of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.

²School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Italy

Key words:Antiphospholipid syndrome, APS, aPL, quality of life, pregnancy, pregnancy complications, pregnancy morbidity, global

Corresponding Author: Savino Sciascia, MD;

CenterforResearch of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, and SCU Nephrology and Dialysis, S. Giovanni Bosco Hospital

Piazza del Donatore di Sangue 3, 10154, Turin, Italy.

Email savino.sciascia@unito.it

Tel +390112402056 Fax +390112402052

This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation

Disclosures: none

Conflict of interest: The authors report no conflict of interest.

Dear Sir,

Early diagnosis of inflammatory joint and connective tissue disease is key to achieving effective treatment and improved prognosis. Notably, it also impacts a patient's quality of life. While the importance of early diagnosis in the management of most rheumatic diseases is undisputable, it is still unrecognised in patients with antiphospholipid syndrome (APS). This is important to address as the prompt identification of antiphospholipid antibodies (aPL) regulates the strategy of treatment, impacting the management in both pregnancy-related and thrombotic-related events, with the ultimate aim of reducing the risk of recurrences and improving patient's prognosis and, thus, their quality of life. For rheumatoid arthritis, diagnostic delays are usually due to gaps between symptoms onset and the referral to a specialist. In patients with APS, in addition, a diagnostic delay might also occur due to the heterogeneity of symptoms and the high prevalence of thrombosis and pregnancy complications in the general population (only a minority of which are attributable to APS). The identification of aPL guides the management of these patients where indefinite anticoagulation will take the place of 3-6 months anticoagulation given in patients with non aPL-related venous thrombosis. Therefore, the diagnostic accuracy of aPL testing is crucial. Current laboratory classification criteria for APS include lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti- β 2GPI (anti- β 2GPI) antibodies. While this panel of tests can correctly identify the great majority of the cases, some patients may be not identified despite overwhelming clinical suspicion of APS.

The diagnostic setbacks have been recently reviewed [1]. Herewith, we will share how the diagnostic challenges reflect in a patient's journey to reach the most effective management strategy.

A 49 years old woman, with a history of six unexplained early miscarriages in her 30s, developed a new onset of purpura at her lower limbs. In the emergency room, her platelet levels were found as low as $4000/\text{mm}^3$ and she was managed with high doses of steroids with gradual resolution of the thrombocytopenia. During the admission she was found to be negative for aCL and anti- $\beta 2\text{GPI}$ antibodies; LA results came back labelled as dubious and not repeated at the time. After 3 months, she presented again to the ER with diffuse abdominal pains and hemiplegic lower limbs with delayed peripheral pulses. Angio-CT scan showed a massive abdominal aortic thrombosis. She successfully underwent emergency surgical aortic thrombectomy, she was started on anticoagulation therapy and she gradually recovered. When her story was re-evaluated at our Center, LA testing results were still reported as equivocal, aCL and anti- $\beta 2\text{GPI}$ antibodies were negative, but she was found to be strongly positive for anti-phosphatidylserine/prothrombin antibodies (aPS/PT), a non-criteria aPL used within the research setting [2]. She is now stable on long-term aspirin and warfarin.

What have we learned from this patient's story? APS is a low-prevalence disease, and patients who suffer from rare diseases often encounter diagnostic difficulties that subjects suffering from more common disorders are spared. Fewer health care providers have enough knowledge and experience to handle a rare disease and usually none or much fewer therapeutic options are available. Moreover, this lack of awareness of the clinical manifestations of a rare disease may lead to a diagnostic delay, a failure of diagnosis, and even misdiagnosis [3,4]. Statistics showed that up to 25% of the patients with a rare disease waited more than 3 years before the correct diagnosis; about 40% were initially misdiagnosed, including 7% who were told that their symptoms were psychological/psychiatric. Patients often must find answers on their own to obtain the

correct diagnosis. Besides, diagnostic delays lead to loss of confidence in the health-care system in about 20% of the patients [REF – Savino questa non so dove trovarla].

In selected cases, given the appropriate clinical setting, aPL testing might go beyond the recommendations of available classification criteria. While it is impossible to determine if the thrombotic event was somehow avoidable, one could speculate that an earlier identification of aPS/PT would have confirmed the suspicion of APS with the immediate establishment of primary thrombo-prophylactic measures. Classification criteria are a set of characteristics that are used to group patients into well-defined homogenous populations that share similar clinical features of a disease. For autoimmune conditions, such criteria are often developed to select homogenous cohorts of patients for clinical research. Although the use of classification criteria as diagnostic is common in clinical practice, their suitability is debated as they do not usually recognise the wide spectrum of clinical manifestations. In fact, in the context of low-prevalence autoimmune conditions, classification criteria fail to encompass all aspects of a disease, including both clinical manifestations and laboratory-based findings.

Undoubtedly, a delay in diagnosis impacts on quality of life and prognosis. During the often quite extended interval between the appearance of the first manifestations of a rare disease and its correct diagnosis, patients live in a diagnostic vacuum if their symptoms remain medically unexplained and lack a follow-up plan. This situation, as Nettleton et al[5] demonstrated, is often described as "a merry-go-round of hope and despair". Such strong feelings suggest that a prolonged pre-diagnostic period is stressful and traumatic and may have serious effects on the mental health of the patients involved, even possibly in the form of post-traumatic stress symptoms.

Since the first description of the syndrome in 1983, the number of antibodies that have been associated to APS is constantly increasing. We are now facing the challenge of correctly attributing value to new antibody specificities, such as aPS/PT and anti-Beta2GPI-domain 1, in the diagnostic algorithm of APS, with the final aim to improve diagnostic accuracy, leading to a better prognosis and quality of life.

Figure 1. Suggested diagnostic algorithm for APS and aPL screening.

References

- 1 Hughes GR V, Khamashta MA. 'Seronegative antiphospholipid syndrome': an update. *Lupus* 2019;**28**:273–4. doi:10.1177/0961203319826358
- 2 Bertolaccini ML, Sciascia S, Murru V, *et al.* Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. *Thromb Haemost* 2013;**109**:207–13. doi:10.1160/TH12-07-0527
- 3 EURORDIS - The Voice of Rare Disease Patients in Europe.
- 4 The Lancet. Listening to patients with rare diseases. *Lancet* 2009;**373**:868. doi:10.1016/S0140-6736(09)60519-5
- 5 Nettleton S, Watt I, O'Malley L, *et al.* Understanding the narratives of people who live with medically unexplained illness. *Patient Educ Couns* 2005;**56**:205–10. doi:10.1016/j.pec.2004.02.010